Nur Nicholson Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Nur Nicholson is Chief Technical Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 81,046 shares of APLS, which is worth approximately $1.65 Million. The most recent transaction as insider was on Jan 13, 2026, when has been sold 2,618 shares (Common Stock) at a price of $22.19 per share, resulting in proceeds of $58,093. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 81K

3.13% 3M change

49.65% 12M change

Total Value Held $1.65 Million

Nur Nicholson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 13 2026	SELL Open market or private sale	$58,093 $22.19 p/Share	2,618 Reduced 3.13%	81,046 Common Stock
Jan 29 2025	SELL Open market or private sale	$24,354 $29.52 p/Share	825 Reduced 0.98%	83,664 Common Stock
Jan 22 2025	SELL Open market or private sale	$120,137 $30.43 p/Share	3,948 Reduced 4.46%	84,489 Common Stock
Jan 21 2025	BUY Grant, award, or other acquisition	-	36,426 Added 29.17%	88,437 Common Stock
Jan 17 2025	SELL Open market or private sale	$64,264 $29.96 p/Share	2,145 Reduced 3.96%	52,011 Common Stock
Jan 13 2025	SELL Open market or private sale	$75,538 $28.7 p/Share	2,632 Reduced 4.63%	54,156 Common Stock
Mar 13 2024	SELL Open market or private sale	$647,618 $57.72 p/Share	11,220 Reduced 16.62%	56,287 Common Stock

Jan 29 2024	SELL Open market or private sale	$53,556 $64.14 p/Share	835 Reduced 1.22%	67,507 Common Stock
Jan 22 2024	SELL Open market or private sale	$168,545 $65.0 p/Share	2,593 Reduced 3.66%	68,342 Common Stock
Jan 16 2024	SELL Open market or private sale	$124,066 $66.81 p/Share	1,857 Reduced 2.55%	70,935 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	19,508 Added 21.14%	72,792 Common Stock
Sep 18 2023	SELL Open market or private sale	$899,063 $44.18 p/Share	20,350 Reduced 27.64%	53,284 Common Stock
Sep 18 2023	BUY Exercise of conversion of derivative security	$289,237 $29.76 p/Share	9,719 Added 11.66%	73,634 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$48,262 $58.5 p/Share	825 Reduced 1.28%	63,503 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	9,886 Added 13.32%	64,328 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$29,076 $52.77 p/Share	551 Reduced 1.0%	54,442 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$105,869 $52.05 p/Share	2,034 Reduced 3.57%	54,993 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	22,580 Added 28.36%	57,027 Common Stock
Apr 25 2022	SELL Other acquisition or disposition	-	1,875 Reduced 5.27%	33,680 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$25,084 $38.59 p/Share	650 Reduced 1.8%	35,555 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	26,051 Added 41.84%	36,205 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	9,375 Added 50.0%	9,375 Common Stock

Nur Nicholson

Chief Technical Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account